Onco-Innovations Initiates Nanoparticle Manufacturing with Dalton Pharma

Onco-Innovations Limited has announced the commencement of manufacturing activities for its proprietary nanoparticle formulation, PEO-b-PBz-CL, in collaboration with Dalton Pharma Services. This initiative aims to produce the necessary nanoparticle materials for progressing preclinical studies of Onco's innovative drug delivery platform, which is intended to work alongside their Polynucleotide Kinase Phosphatase (PNKP) inhibitor.

The production process will focus on optimizing and scaling up methods to ensure the formulation's adherence to quality specifications. Dalton is tasked with reducing residual catalyst content and escalating production from 10 grams to 350 grams. This effort will also generate critical analytical data to support regulatory submissions and facilitate the transition to GMP manufacturing.

By partnering with Dalton, Onco-Innovations gains access to extensive technical expertise and regulatory experience. This collaboration aims to provide a comprehensive development package that ensures a seamless progression towards clinical readiness.